{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T09:34:30Z","timestamp":1771148070281,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.bmcl.2020.127428","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T11:57:40Z","timestamp":1595505460000},"page":"127428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3858-8650","authenticated-orcid":false,"given":"Ralph","family":"Kirk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Betson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matilda","family":"Bingham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Huxley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Moat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Pesnot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Tait","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Hallworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2020.127428_b0005","unstructured":"Drug Trials Snapshots: BAXDELA | FDA. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshots-baxdela."},{"key":"10.1016\/j.bmcl.2020.127428_b0010","unstructured":"FDA Approves New Indication for Delafloxacin for CABP. Medscape. Accessed December 10, 2019. http:\/\/www.medscape.com\/viewarticle\/920429."},{"issue":"10","key":"10.1016\/j.bmcl.2020.127428_b0015","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1128\/AAC.00941-16","article-title":"In vitro activity of delafloxacin tested against isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis","volume":"60","author":"Flamm","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"issue":"2","key":"10.1016\/j.bmcl.2020.127428_b0020","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.01201-10","article-title":"Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus","volume":"55","author":"Lemaire","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"issue":"5","key":"10.1016\/j.bmcl.2020.127428_b0025","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/OLQ.0000000000000971","article-title":"Efficacy and Safety of Single-Dose Oral Delafloxacin Compared With Intramuscular Ceftriaxone for Uncomplicated Gonorrhea Treatment","volume":"46","author":"Hook","year":"2019","journal-title":"Sex Transm Dis."},{"issue":"10","key":"10.1016\/j.bmcl.2020.127428_b0030","article-title":"Safety of delafloxacin: Focus on adverse events of special interest. Open Forum","volume":"5","author":"Lodise","year":"2018","journal-title":"Infect Dis."},{"issue":"19","key":"10.1016\/j.bmcl.2020.127428_b0035","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1706988","article-title":"Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea","volume":"379","author":"Taylor","year":"2018","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.bmcl.2020.127428_b0040","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/cid\/ciy145","article-title":"Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation","volume":"67","author":"Taylor","year":"2018","journal-title":"Clin Infect Dis."},{"issue":"10","key":"10.1016\/j.bmcl.2020.127428_b0045","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01131-19","article-title":"In Vivo Pharmacodynamic Target Determination for Delafloxacin against Klebsiella pneumoniae and Pseudomonas aeruginosa in the Neutropenic Murine Pneumonia Model","volume":"63","author":"Zhao","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.bmcl.2020.127428_b0050","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2147\/DDDT.S106071","article-title":"Delafloxacin: Design, development and potential place in therapy","volume":"11","author":"Candel","year":"2017","journal-title":"Drug Des Devel Ther."},{"issue":"2","key":"10.1016\/j.bmcl.2020.127428_b0055","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40121-018-0198-x","article-title":"Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties","volume":"7","author":"Jorgensen","year":"2018","journal-title":"Infect Dis Ther."},{"issue":"21","key":"10.1016\/j.bmcl.2020.127428_b0060","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1021\/jm901241e","article-title":"Escape from flatland: Increasing saturation as an approach to improving clinical success","volume":"52","author":"Lovering","year":"2009","journal-title":"J Med Chem."},{"issue":"10","key":"10.1016\/j.bmcl.2020.127428_b0065","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1039\/C9MD00120D","article-title":"Quinolone antibiotics","volume":"10","author":"Pham","year":"2019","journal-title":"MedChemComm."},{"issue":"20","key":"10.1016\/j.bmcl.2020.127428_b0070","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1021\/jm990191k","article-title":"Synthesis and Antimicrobial Activity of 4H\u20134-Oxoquinolizine Derivatives: Consequences of Structural Modification at the C-8 Position","volume":"42","author":"Ma","year":"1999","journal-title":"J Med Chem."},{"issue":"10","key":"10.1016\/j.bmcl.2020.127428_b0075","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1021\/bi5000564","article-title":"Mechanism of Quinolone Action and Resistance","volume":"53","author":"Aldred","year":"2014","journal-title":"Biochemistry"},{"issue":"10","key":"10.1016\/j.bmcl.2020.127428_b0080","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1248\/cpb.42.2049","article-title":"Pyridonecarboxylic acids as antibacterial agents. VI. Synthesis and structure-activity relationship of 7-(alkyl, cycloalkyl, and vinyl)-1-cyclopropyl-6-fluoro-4-quinolone-3-carboxylic acids","volume":"42","author":"Todo","year":"1994","journal-title":"Chem Pharm Bull (Tokyo)."},{"key":"10.1016\/j.bmcl.2020.127428_b0085","unstructured":"Yazaki A, Niino Y, Ohshita Y, et al. Novel pyridonecarboxylic acid derivatives or their salts and antibacterial agent comprising the same as the active ingredient. EP0911327."},{"issue":"16","key":"10.1016\/j.bmcl.2020.127428_b0090","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1039\/p19750001574","article-title":"A new method for the deoxygenation of secondary alcohols","author":"Barton","year":"1975","journal-title":"J. Chem. Soc., Perkin Trans. 1"},{"key":"10.1016\/j.bmcl.2020.127428_b0095","unstructured":"Brown MF, Che Y, Marfat A, Melnick MJ, Montgomery JI, Reilly U. N-linked hydroxamic acid derivatives useful as antibacterial agents. WO\/2011\/073845."},{"issue":"23","key":"10.1016\/j.bmcl.2020.127428_b0100","doi-asserted-by":"crossref","first-page":"10144","DOI":"10.1021\/jm501552x","article-title":"Trends and Exceptions of Physical Properties on Antibacterial Activity for Gram-Positive and Gram-Negative Pathogens","volume":"57","author":"Brown","year":"2014","journal-title":"J Med Chem."},{"issue":"11","key":"10.1016\/j.bmcl.2020.127428_b0105","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1093\/jac\/dkw288","article-title":"The novel 2016 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization","volume":"71","author":"Unemo","year":"2016","journal-title":"J Antimicrob Chemother."},{"issue":"12","key":"10.1016\/j.bmcl.2020.127428_b0110","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat Rev Drug Discov."},{"issue":"4","key":"10.1016\/j.bmcl.2020.127428_b0115","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3109\/14756360903373350","article-title":"Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects","volume":"25","author":"Sharma","year":"2010","journal-title":"J Enzyme Inhib Med Chem."},{"issue":"1","key":"10.1016\/j.bmcl.2020.127428_b0120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijpharm.2014.04.034","article-title":"Novel organic salts based on fluoroquinolone drugs: Synthesis, bioavailability and toxicological profiles","volume":"469","author":"Florindo","year":"2014","journal-title":"Int J Pharm."},{"issue":"8","key":"10.1016\/j.bmcl.2020.127428_b0125","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/jps.22537","article-title":"Fluoroquinolone salts with carboxylic acids","volume":"100","author":"Reddy","year":"2011","journal-title":"J Pharm Sci."},{"key":"10.1016\/j.bmcl.2020.127428_b0130","doi-asserted-by":"crossref","unstructured":"Blokhina SV, Sharapova AV, Ol\u2019khovich MV, Volkova TV, Perlovich GL. Solubility, lipophilicity and membrane permeability of some fluoroquinolone antimicrobials. Eur J Pharm Sci. 2016;93:29-37. doi:10.1016\/j.ejps.2016.07.016.","DOI":"10.1016\/j.ejps.2016.07.016"},{"issue":"4","key":"10.1016\/j.bmcl.2020.127428_b0135","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1515\/amma-2015-0084","article-title":"Quinolone Antibacterials: Commentary and Considerations Regarding UV Spectra and Chemical Structure","volume":"61","author":"Aura","year":"2015","journal-title":"Acta Medica Marisiensis."},{"issue":"6","key":"10.1016\/j.bmcl.2020.127428_b0140","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1128\/AAC.04813-14","article-title":"A Thorough QT Study To Evaluate the Effects of Therapeutic and Supratherapeutic Doses of Delafloxacin on Cardiac Repolarization","volume":"59","author":"Litwin","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"issue":"12","key":"10.1016\/j.bmcl.2020.127428_b0145","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1086\/508873","article-title":"Antimicrobial-Associated QT Interval Prolongation: Pointes of Interest","volume":"43","author":"Goldstein","year":"2006","journal-title":"Clin Infect Dis."},{"issue":"1","key":"10.1016\/j.bmcl.2020.127428_b0150","first-page":"122","article-title":"Interactions of a Series of Fluoroquinolone Antibacterial Drugs with the Human Cardiac K + Channel HERG","volume":"59","author":"Kang","year":"2001","journal-title":"Mol Pharmacol."}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X20305394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X20305394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:36:23Z","timestamp":1760772983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X20305394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":30,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0960894X20305394"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2020.127428","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2020.127428","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127428"}}